STTK
Shattuck Labs Inc.
$6.68
+$0.26(+4.05%)
56
Overall
60
Value
66
Tech
44
Quality
Market Cap
$460.16M
Volume
343.25K
52W Range
$0.69 - $6.81
Target Price
$10.00
Company Overview
| Mkt Cap | $460.16M | Price | $6.68 |
| Volume | 343.25K | Change | +4.05% |
| P/E Ratio | -6.1 | Open | $6.39 |
| Revenue | $5.7M | Prev Close | $6.42 |
| Net Income | $-75.4M | 52W Range | $0.69 - $6.81 |
| Div Yield | N/A | Target | $10.00 |
| Overall | 56 | Value | 60 |
| Quality | 44 | Technical | 66 |
No chart data available
About Shattuck Labs Inc.
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate is SL-325, a monoclonal antibody which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Sector: Industrials
Industry: Pharmaceutical Preparation Manufacturing
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | STTK | $6.68 | +4.0% | 343.25K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |